BCMA / Luciferase - CHO Recombinant Cell Line

Catalog #

79724

$9,780 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant CHO-K1 cells constitutively expressing both the human BCMA protein (B-Cell Maturation Antigen or CD269, GenBank accession #NM_001192) and the firefly luciferase reporter. Surface expression of BCMA was confirmed by flow cytometry.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Synonyms

TNFRSF17, BCM, BCMA, CD269, TNFRSF13A, tumor necrosis factor receptor superfamily member 17

●

Product Data Gallery

FACS analysis of cell surface expression of BCMA in BCMA / Luciferase CHO recombinant cells

Luciferase activity of BCMA / Luciferase CHO recombinant cells

Product Info

Storage and Usage

Citations

Host Cell Line

CHO K1. Chinese Hamster Ovary.

Supplied As

Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.

Materials Required But Not Supplied

• Thaw Medium 3 (BPS Bioscience, #60186)
• Growth Medium 3A (BPS Bioscience, #60188)
• 96-well tissue culture-treated white clear-bottom assay plate
• ONE-Step luciferase assay system (BPS Bioscience, #60690) or other luciferase
reagent for measuring firefly luciferase activity
• Luminometer

UniProt #

Q02223

Mycoplasma Testing

This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.

Background

B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy not only because of its restricted expression in non-malignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T-cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy the breakthrough designation in treating Multiple Myeloma.

Storage/Stability

Store in liquid nitrogen immediately upon receipt.

Culture Conditions

For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.

Thaw medium 3 (BPS Bioscience, #60186): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin

Growth Medium 3A (BPS Bioscience #60188): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 1 mg/ml of Geneticin and 500 μg/ml of Hygromycin B to ensure recombinant expression.

Instructions for Use

See data sheet for detailed culturing and assay protocol.

Shipping Temperature

-80°C

Notes

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid multiple freeze/thaw cycles.

Scientific Category

Immunotherapy

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

BCMA / Luciferase - CHO Recombinant Cell Line

PRODUCTS

SERVICES

RESOURCES

COMPANY